CAT
Basic information
Region (hg38): 11:34438934-34472060
Links
Phenotypes
GenCC
Source:
- acatalasia (Supportive), mode of inheritance: AR
- acatalasia (Strong), mode of inheritance: AR
- acatalasia (Moderate), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Acatalasemia | AR | Allergy/Immunology/Infectious; Pharmacogenomic | Individuals may be prone to manifestations such as oral ulcers and gangrene, and prompt treatment of infections may be beneficial; Pharmacogenomically, variants may be related to adverse reactions with treatment with medications such as uric acid oxidase | Allergy/Immunology/Infectious | 12991731; 13904105; 2308162; 1999334; 1591863; 1551654; 8673475; 11117918; 11001624; 11197178; 11603354; 11500062; 15771551; 15800961; 17729111 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CAT gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | |||||
missense | 16 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 2 | |||||
splice region | 1 | 2 | 3 | |||
non coding | 0 | |||||
Total | 0 | 2 | 9 | 11 | 6 |
Variants in CAT
This is a list of pathogenic ClinVar variants found in the CAT region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
11-34438994-T-C | Benign (-) | |||
11-34449321-C-CGA | Acatalasia | Pathogenic (Apr 01, 2000) | ||
11-34450983-G-A | Benign (Aug 10, 2018) | |||
11-34451031-C-T | Likely benign (May 15, 2018) | |||
11-34451076-C-T | Benign (Dec 31, 2019) | |||
11-34451102-A-T | Benign (Dec 31, 2019) | |||
11-34452084-AT-A | Acatalasemia, japanese type | Pathogenic (Jan 01, 1995) | ||
11-34452212-G-A | Acatalasemia, japanese type | Pathogenic (Mar 01, 1992) | ||
11-34453135-C-A | Likely benign (Apr 24, 2018) | |||
11-34453139-A-C | not specified | Uncertain significance (May 31, 2022) | ||
11-34453164-C-T | Benign (Jul 23, 2018) | |||
11-34453174-C-T | Benign (Dec 31, 2019) | |||
11-34453839-A-T | Likely benign (Apr 12, 2018) | |||
11-34453840-C-T | not specified | Likely benign (Nov 07, 2023) | ||
11-34453862-G-T | not specified | Uncertain significance (Feb 01, 2023) | ||
11-34456025-C-A | CAT-related disorder | Benign (Dec 31, 2019) | ||
11-34456170-A-G | Likely benign (Dec 31, 2019) | |||
11-34456194-C-T | not specified | Uncertain significance (May 24, 2023) | ||
11-34456207-G-T | Acatalasia • CAT-related disorder | Conflicting classifications of pathogenicity (Dec 31, 2019) | ||
11-34456758-G-A | not specified | Uncertain significance (Sep 17, 2021) | ||
11-34456813-T-C | not specified | Uncertain significance (Jan 04, 2024) | ||
11-34456818-G-C | Acatalasia | Likely pathogenic (Jan 25, 2023) | ||
11-34461246-T-C | Likely benign (Dec 17, 2018) | |||
11-34461249-A-G | Likely pathogenic (Aug 21, 2017) | |||
11-34461361-C-T | Benign (-) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CAT | protein_coding | protein_coding | ENST00000241052 | 13 | 33138 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.63e-10 | 0.597 | 125671 | 0 | 77 | 125748 | 0.000306 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.0780 | 316 | 312 | 1.01 | 0.0000188 | 3515 |
Missense in Polyphen | 151 | 154.42 | 0.97784 | 1785 | ||
Synonymous | -0.346 | 112 | 107 | 1.04 | 0.00000624 | 982 |
Loss of Function | 1.34 | 19 | 26.4 | 0.719 | 0.00000130 | 301 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00118 | 0.00118 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000326 | 0.000326 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000159 | 0.000141 |
Middle Eastern | 0.000326 | 0.000326 |
South Asian | 0.000882 | 0.000850 |
Other | 0.000652 | 0.000652 |
dbNSFP
Source:
- Function
- FUNCTION: Occurs in almost all aerobically respiring organisms and serves to protect cells from the toxic effects of hydrogen peroxide. Promotes growth of cells including T-cells, B-cells, myeloid leukemia cells, melanoma cells, mastocytoma cells and normal and transformed fibroblast cells. {ECO:0000269|PubMed:7882369}.;
- Disease
- DISEASE: Acatalasemia (ACATLAS) [MIM:614097]: A metabolic disorder characterized by a total or near total loss of catalase activity in red cells. It is often associated with ulcerating oral lesions. Acatalasemia is inherited as an autosomal recessive trait. {ECO:0000269|PubMed:2308162}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Tryptophan metabolism - Homo sapiens (human);Doxorubicin Pathway (Cancer Cell), Pharmacodynamics;Longevity regulating pathway - multiple species - Homo sapiens (human);Peroxisome - Homo sapiens (human);Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human);FoxO signaling pathway - Homo sapiens (human);Longevity regulating pathway - Homo sapiens (human);Doxorubicin Pathway, Pharmacokinetics;Glyoxylate and dicarboxylate metabolism - Homo sapiens (human);Oxidative Stress Pathway (Erythrocyte);Pathway_PA165980337;Oxidative Stress Pathway (Erythrocyte);Oxidative Stress Regulatory Pathway (Erythrocyte);Disulfiram Action Pathway;Degradation of Superoxides;Ethanol Degradation;Tryptophan Metabolism;Selenium Micronutrient Network;Folate Metabolism;Amyotrophic lateral sclerosis (ALS);Oxidative Stress;Tryptophan metabolism;DNA Damage Response (only ATM dependent);Neutrophil degranulation;Detoxification of Reactive Oxygen Species;Cellular responses to stress;Metabolism of proteins;Innate Immune System;Immune System;ethanol degradation IV;Peroxisomal protein import;Cellular responses to external stimuli;the igf-1 receptor and longevity;Tryptophan degradation;reactive oxygen species degradation;FoxO family signaling
(Consensus)
Recessive Scores
- pRec
- 0.950
Intolerance Scores
- loftool
- 0.221
- rvis_EVS
- -0.31
- rvis_percentile_EVS
- 32.15
Haploinsufficiency Scores
- pHI
- 0.496
- hipred
- Y
- hipred_score
- 0.516
- ghis
- 0.532
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 1.00
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cat
- Phenotype
- neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cellular phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- response to reactive oxygen species;osteoblast differentiation;ureteric bud development;response to hypoxia;protein targeting to peroxisome;triglyceride metabolic process;aging;cholesterol metabolic process;aerobic respiration;response to light intensity;UV protection;response to ozone;response to lead ion;positive regulation of phosphatidylinositol 3-kinase signaling;response to activity;response to inactivity;hemoglobin metabolic process;negative regulation of NF-kappaB transcription factor activity;response to estradiol;response to insulin;response to vitamin A;response to vitamin E;response to L-ascorbic acid;cellular response to oxidative stress;response to hydrogen peroxide;hydrogen peroxide catabolic process;negative regulation of apoptotic process;neutrophil degranulation;response to ethanol;response to cadmium ion;positive regulation of NF-kappaB transcription factor activity;protein tetramerization;protein homotetramerization;positive regulation of cell division;response to hyperoxia;response to fatty acid;cellular response to growth factor stimulus;response to phenylpropanoid;cellular oxidant detoxification
- Cellular component
- extracellular region;mitochondrial intermembrane space;lysosome;peroxisome;peroxisomal membrane;peroxisomal matrix;endoplasmic reticulum;Golgi apparatus;cytosol;plasma membrane;focal adhesion;membrane;secretory granule lumen;intracellular membrane-bounded organelle;extracellular exosome;ficolin-1-rich granule lumen
- Molecular function
- aminoacylase activity;catalase activity;signaling receptor binding;antioxidant activity;oxidoreductase activity, acting on peroxide as acceptor;enzyme binding;heme binding;identical protein binding;protein homodimerization activity;metal ion binding;NADP binding